Similar results with CD4+ T-cell depletion and reduced therapeutic response were observed when a group used a stimulator of interferon genes (STING) agonist alongside OX40R agonist with PD-L1 blockade in a NT2.5 breast cancer model [49]. The gene discussed is STING1; the disease is breast carcinoma.